Braidwell
$2.6B 13F equity value
106 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Braidwell covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| CAI | CARIS LIFE SCIENCES INC | 8,256,032 | $147M | 5.6% |
| HNGE | HINGE HEALTH INC | 1,330,127 | $110M | 4.2% |
| GKOS | GLAUKOS CORP | 591,927 | $83M | 3.2% |
| EWTX | EDGEWISE THERAPEUTICS INC | 1,996,965 | $81M | 3.1% |
| SYRE | SPYRE THERAPEUTICS INC | 879,467 | $78M | 3.0% |
| IRTC | IRHYTHM HOLDINGS INC | 654,262 | $78M | 3.0% |
| NEO | NEOGENOMICS INC | 4,918,202 | $72M | 2.8% |
| KOD | KODIAK SCIENCES INC | 1,787,318 | $70M | 2.7% |
| XENE | XENON PHARMACEUTICALS INC | 1,131,452 | $68M | 2.6% |
| GLUE | MONTE ROSA THERAPEUTICS INC | 2,451,562 | $59M | 2.3% |
Track Braidwell's 13F portfolio: $2.6B in reported holdings, 106 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}